Zobrazeno 1 - 6
of 6
pro vyhledávání: '"A Milillo Naraine"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Cesar A. Santa-Maria, David B. Page, Yongqiang Tang, Julie R. Nangia, Laura Spring, Leif W. Ellisen, Andre K. D. Liem, Adrianna Milillo Naraine, Erika Hamilton, James Reeves, Ming Shan, Hanna Irie, Minetta C. Liu, Steven J. Isakoff, Hyo S. Han, J.R. Graham, Meghan Duncan
Publikováno v:
Cancer Research. 80:P3-11
Background: Niraparib is a selective poly(ADP-ribose) polymerase 1/2 inhibitor that has demonstrated antitumor activity in advanced triple-negative breast cancer (TNBC) in combination with a programmed cell death 1 inhibitor, with the greatest clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b479f5edfe29b0529449b1e543c892ff
https://doi.org/10.1158/1538-7445.sabcs19-p3-11-03
https://doi.org/10.1158/1538-7445.sabcs19-p3-11-03
Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors
Autor:
Zev A. Wainberg, RL Moroose, Anna Plotka, Linh Nguyen, Justin Hoffman, David Kanamori, Jayeta Chakrabarti, Adriana Milillo Naraine, Diane Wang
Publikováno v:
Anti-Cancer Drugs
Anti-cancer drugs, vol 30, iss 5
Anti-cancer drugs, vol 30, iss 5
Supplemental Digital Content is available in the text.
The aims of this study were (i) to evaluate the effect of talazoparib (1 mg once daily) on cardiac repolarization in patients with advanced solid tumors by assessing corrected QT interval (Q
The aims of this study were (i) to evaluate the effect of talazoparib (1 mg once daily) on cardiac repolarization in patients with advanced solid tumors by assessing corrected QT interval (Q
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83a4a7d43efdbec9c15b024a5a43735f
https://doi.org/10.1097/cad.0000000000000772
https://doi.org/10.1097/cad.0000000000000772
Autor:
Linh Nguyen, Diane D. Wang, Anna Plotka, Zev A. Wainberg, A Milillo Naraine, D Kanamori, Justin Hoffman, Jayeta Chakrabarti, RL Moroose, S Babu
Publikováno v:
Cancer Research. 79:P3-14
Background: Talazoparib (TAL), an oral poly ADP-ribose polymerase inhibitor, is under investigation in multiple oncologic clinical trials and has been submitted to the US FDA for use in patients (pts) with germline BRCA-mutated, HER2-negative advance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::702b09d09277a8db2eb35a51a1d338d8
https://doi.org/10.1158/1538-7445.sabcs18-p3-14-07
https://doi.org/10.1158/1538-7445.sabcs18-p3-14-07
Autor:
David B. Page, Cesar A. Santa-Maria, K. Sun, P. Pan, Hanna Irie, Minetta C. Liu, A Milillo Naraine, Julie R. Nangia, Erika Hamilton, Hyo S. Han, J.R. Graham, Steven J. Isakoff, Ming Shan, James Reeves, Leif W. Ellisen, Andre K. D. Liem, Laura Spring
Publikováno v:
Annals of Oncology. 30:v71
Background Niraparib is a selective oral poly(ADP-ribose) polymerase 1/2 inhibitor (PARPi) approved as maintenance treatment of recurrent ovarian cancer. Previous studies revealed unique pharmacological properties of niraparib, including a large volu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28015694b583af733cd60f8d1119dd42
https://doi.org/10.1093/annonc/mdz240.036
https://doi.org/10.1093/annonc/mdz240.036
Autor:
Hoffman, Justin, Chakrabarti, Jayeta, Plotka, Anna, Milillo Naraine, Adriana, Kanamori, David, Moroose, Rebecca, Nguyen, Linh, Wang, Diane, Wainberg, Zev A.
Publikováno v:
Anti-Cancer Drugs; Jun2019, Vol. 30 Issue 5, p523-532, 10p